Andrew T. Chan, MD, MPH
Program Director, Gastroenterology Training Program
- Department of Medicine
- Cancer Center
- Cancer Risk Assessment
- Digestive Healthcare Center
- Colorectal Center
- Clinical Interests
- Cancer prevention
- General gastroenterology
- Colon and rectal cancer
- Hereditary colorectal cancer
- Gastrointestinal cancer
- Boston: Massachusetts General Hospital
- Medical Education
- MD, Harvard Medical School
- M.P.H., Harvard School of Public Health
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Gastroenterology, American Board of Internal Medicine
- Accepting New Patients
- Insurances Accepted
- Aetna Health Inc.
Blue Cross Blue Shield - Blue Care 65
Blue Cross Blue Shield - Indemnity
Blue Cross Blue Shield - Managed Care
Blue Cross Blue Shield - Partners Plus
Cigna (PAL #'s)
Fallon Community HealthCare
Great-West Healthcare (formally One Health Plan)
Harvard Pilgrim Health Plan - other
Harvard Pilgrim Health Plan - PBO
Health Care Value Management (HCVM)
Humana/Choice Care PPO
Medicare - ACD
Neighborhood Health Plan - ACD
Neighborhood Health Plan - PBO
OSW - Maine
OSW - New Hampshire
OSW - Rhode Island
OSW - Vermont
Private Health Care Systems (PHCS)
Railroad Medicare - ACD
Senior Whole Health
Tufts Health Plan
United Healthcare (non-HMO) - ACD
United Healthcare (non-HMO) - PBO
View my most recent publications at PubMed
- Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, Imamura Y, Willett WC, Rosner BR, Fuchs CS, Giovannucci E, Ogino S , Chan AT (co-senior authors). Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013. 369(12):1095-105.
- Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT , Ogino S (co-senior authors). Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013. 309: 2563-71. PMCID: PMC3743040
- Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian Z, Baba Y, Shima K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT , Ogino S (co-senior authors). Aspirin use, PIK3CA mutation, and colorectal cancer survival. N Engl J Med. 2012; 367: 1596-606. PMCID: PMC3532946
- Chan AT, Ogino S, Giovannucci EL, Fuchs CS. Inflammatory markers are associated with risk of colorectal cancer and chemopreventative response to anti-inflammatory drugs. Gastroenterology. 2011. 140(3): 799-808. PMCID: PMC3049858
- Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649-58. PMCID: PMC2848289. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131-42.
Aspirin therapy's ability to reduce the risk of colorectal cancer, an association seen in a large number of studies, appears to depend on the drug's inhibition of the COX-2 enzyme, the action that also underlies aspirin's usefulness for treating pain and inflammation.
Regular use of aspirin after colorectal cancer diagnosis may reduce the risk of cancer death, report investigators from Massachusetts General Hospital, Dana-Farber Cancer Institute and Brigham and Women’s Hospital.
The reduced risk of colorectal cancer associated with taking aspirin or other nonsteroidal anti-inflammatory drugs may be limited to individuals already at risk because of elevations in a specific inflammatory factor in the blood.
A new study finds that colonoscopy appears to reduce the risk of developing or dying from colorectal cancer more powerfully than does sigmoidoscopy, a similar procedure that examines only a portion of the colon. The investigation also identifies molecular features that may help explain tumors that are diagnosed despite an individual's having recently undergone colonoscopy.
Researchers from MGH, Dana-Farber Cancer Institute and Case Western Reserve School of Medicine have shown that aspirin’s previous reported ability to reduce the risk of colorectal cancer applies only to individuals with high levels of a specific gene product in their colons.
55 Fruit Street
Boston, MA 02114-2696
U.S. News & World Report ranks Mass General gastroenterology third among U.S. hospitals.